1. Home
  2. CLPS vs XLO Comparison

CLPS vs XLO Comparison

Compare CLPS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CLPS Incorporation

CLPS

CLPS Incorporation

HOLD

Current Price

$1.01

Market Cap

36.0M

Sector

Technology

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$7.39

Market Cap

39.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPS
XLO
Founded
2005
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
39.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CLPS
XLO
Price
$1.01
$7.39
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
7.0K
350.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
12.74%
N/A
EPS Growth
N/A
60.79
EPS
N/A
N/A
Revenue
N/A
$6,344,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.46
52 Week High
$1.88
$8.09

Technical Indicators

Market Signals
Indicator
CLPS
XLO
Relative Strength Index (RSI) 43.95 97.16
Support Level $0.90 $0.64
Resistance Level $1.08 N/A
Average True Range (ATR) 0.05 0.17
MACD -0.01 0.71
Stochastic Oscillator 48.20 93.05

Price Performance

Historical Comparison
CLPS
XLO

About CLPS CLPS Incorporation

CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: